Irinotecan hydrochloride-containing drug composition and preparation method thereof

A technology for irinotecan hydrochloride and its composition, which is applied in the field of pharmaceutical composition containing irinotecan hydrochloride and its preparation, can solve the problems of failure to meet the registration standards of imported drugs, poor stability of original research products, and high equipment requirements, etc., and achieve reduction The effect of drug risk, no special equipment requirements, and simple preparation method

Active Publication Date: 2018-12-14
SICHUAN HUIYU PHARMA
View PDF3 Cites 4 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0005] CN102885765A discloses an injection containing lactic acid, sorbitol, and irinotecan hydrochloride. During preparation, a metal filter element is used for decarbonization, and a rotating water bath is used for sterilization, so as to more effectively control the amount of related substances, but the preparation method requires equipment Very high, and the applicant of the present invention prepared the sample according to the prescription and preparation method described in its embodiment 1, placed it for 36 months for a long time, found that the content of other individual impurities was 0.15%, the total impurity content was 1.58%, and the impurity level was still high , unable to meet the requirements of the registration standards for imported drugs
[0006] In addition, we also studied the impurity levels of the reference preparation of irinotecan injection listed by the original research company Pfizer in different periods, and found that although the impurities of the original research product can meet the requirements of the registration standards for imported drugs within the shelf life (36 months), the samples were tested. After the accelerated test, it was found that the content of other individual impurities in some batches of samples exceeded 0.1% and reached 0.39% when accelerated for 6 months, indicating that the stability of the original research product was poor under accelerated conditions, and the content of other individual impurities increased rapidly, and the product quality still needs to be improved. further improvement
[0007] The impurity level in medicines can reflect the stability of product quality. Lower impurity level means better product stability, higher safety, and is more conducive to patient drug safety. However, the existing technology has not yet solved the problem of hydrochloric acid. The stability of irinotecan injection still requires in-depth research on the prescription and preparation method of the injection to provide a low-cost irinotecan hydrochloride injection with long-term stability and no special requirements for production equipment

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Irinotecan hydrochloride-containing drug composition and preparation method thereof
  • Irinotecan hydrochloride-containing drug composition and preparation method thereof
  • Irinotecan hydrochloride-containing drug composition and preparation method thereof

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0085]

[0086] Step (1): Pre-dissolve lactic acid with water for injection at 65°C~75°C and add it to the mixing tank;

[0087] Step (2): Pre-dissolve irinotecan hydrochloride with water for injection at 20°C to 30°C and add it to the mixing tank;

[0088] Step (3): Pre-dissolve sorbitol with water for injection at 20°C to 30°C and add it to the mixing tank;

[0089] Step (4): Pass process hot water through the jacket of the liquid mixing tank to heat the liquid medicine to 65℃~75℃;

[0090] Step (5): Add water for injection to 80%-85% of the prepared volume, mix well, pass chilled water through the mixing tank to control the temperature of the liquid to 20℃~30℃, check that the solution should be a light yellow clear liquid;

[0091] Step (6): Adjust the pH of the drug solution to 3.2 with sodium hydroxide solution or hydrochloric acid solution, and then add water for injection at 20°C to 30°C to the final volume;

[0092] Step (7): Fill the batching tank with nitrogen filtered by a 0.2...

Embodiment 2

[0100]

[0101] Prepare injection according to the following method:

[0102] Step (1): Pre-dissolve lactic acid with water for injection at 65°C~75°C and add it to the mixing tank, adjust the pH to 4.0 with sodium hydroxide solution or hydrochloric acid solution;

[0103] Step (2): Pre-dissolve irinotecan hydrochloride with water for injection at 20°C to 30°C and add it to the mixing tank;

[0104] Step (3): Pre-dissolve sorbitol with water for injection at 20°C to 30°C and add it to the mixing tank;

[0105] Step (4): Heat the liquid medicine to 65℃~75℃ through process hot water in the jacket of the liquid mixing tank, and stir to dissolve the medicine;

[0106] Step (5): Add water for injection to 80%-85% of the prepared volume, mix well, pass chilled water through the mixing tank to control the temperature of the liquid to 20℃~30℃, check that the solution should be a light yellow clear liquid;

[0107] Step (6): Adjust the pH of the drug solution to 3.2 with sodium hydroxide solution...

Embodiment 3

[0116] Prepare injections according to the prescription described in Example 1 and the preparation method described in Example 1. The difference is that step (1) pre-dissolve lactic acid with water for injection at 65°C~75°C and add it to the dosing tank, then use sodium hydroxide The solution or hydrochloric acid solution adjusts the pH of the lactic acid aqueous solution to 4.5, and then performs subsequent operations.

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The invention provides an irinotecan hydrochloride-containing drug composition and a preparation method thereof. The preparation method comprises the following steps: before irinotecan hydrochloride is added into a lactic acid aqueous solution, adjusting the lactic acid aqueous solution to a specific pH range at first, and then after the irinotecan hydrochloride, sorbitol and injection water are added, adjusting medicinal liquid to the specific pH range. Through twice pH value adjustment, the long-term stability of the injection can be obviously improved, and impurities can be reduced; the drug use risk of a patient is greatly lowered; meanwhile, the preparation method is simple; no special equipment requirement is needed; the production cost is obviously reduced.

Description

Technical field [0001] The present invention relates to a pharmaceutical composition, and more specifically, to a pharmaceutical composition containing irinotecan hydrochloride and a preparation method thereof. Background technique [0002] Irinotecan hydrochloride (Irinotecan), chemical name (+)-(4S)-4,11-diethyl-4-hydroxy-9[(4-piperidinylpiperidine) carbonyl]-1H-pyrano [3',4': 6,7] Indoleazine [1,2-b] Quinoline-3,14-(4H,12H)-dione hydrochloride, is a semi-synthetic water-soluble camptothecin Class derivatives. The drug and its metabolite SN38 are DNA topoisomerase I inhibitors. The complex formed with topoisomerase I and DNA can cause DNA single-strand breaks, prevent DNA replication and inhibit RNA synthesis. The first-line medication for advanced colorectal cancer also has certain effects on lung cancer, breast cancer, and pancreatic cancer. [0003] Because irinotecan hydrochloride is slightly soluble in water, and the resulting aqueous solution is easily degraded by environ...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Applications(China)
IPC IPC(8): A61K9/08A61K47/26A61K47/12A61K31/4745A61P35/00
CPCA61K9/0019A61K9/08A61K31/4745A61K47/12A61K47/26A61P35/00
Inventor 胡和平丁兆刘云龙韩江萍
Owner SICHUAN HUIYU PHARMA
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap